TYME Technologies is a biotechnology company that develops cancer therapeutics. It provides SM-88, a cancer metabolism-based therapy (CMBT) that is based on its proprietary tyrosine derivative and designed to interrupt the metabolic processes of cancer cells. SM-88 can be used to treat both solid and liquid tumors, including pancreatic, lung, breast, prostate, and sarcoma cancers.